1,2-Ethanediamine, N-{3-(trimethoxysilyl)propyl}-,N-{(ethenylphenyl)methyl}derivate,hydrochlorides

Skin sensitisation

Administrative data

Endpoint:

skin sensitisation: in vivo (LLNA)

Type of information:

experimental study

Adequacy of study:

key study

Study period:

08 - 21 Jun 2005

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2005

Report date:

2005

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)

Version / remarks:

2002

Deviations:

no

Test guideline 2

Qualifier:

according to guideline

Guideline:

EPA OPPTS 870.2600 (Skin Sensitisation)

Version / remarks:

2003

Deviations:

no

GLP compliance:

yes

Type of study:

mouse local lymph node assay (LLNA)

Test material

Test material information

Constituent 1

Reference substance name:

(2-aminoethyl)[(4-ethenylphenyl)methyl][3-(trimethoxysilyl)propyl]azanium (2-azaniumylethyl)[3-(trimethoxysilyl)propyl]amine 11-(4-ethenylphenyl)-10-[(4-ethenylphenyl)methyl]-3,3-dimethoxy-2-oxa-7,10-diaza-3-silaundecan-7-ium 11-(4-ethenylphenyl)-3,3-dimethoxy-2-oxa-7,10-diaza-3-silaundecan-7-ium 11-(4-ethenylphenyl)-7,10-bis[(4-ethenylphenyl)methyl]-3,3-dimethoxy-2-oxa-7,10-diaza-3-silaundecan-7-ium 11-(4-ethenylphenyl)-7-[(4-ethenylphenyl)methyl]-3,3-dimethoxy-2-oxa-7,10-diaza-3-silaundecan-7-ium hexachloride

EC Number:

605-620-0

Cas Number:

171869-89-9

Molecular formula:

Not applicable to UVCB

IUPAC Name:

(2-aminoethyl)[(4-ethenylphenyl)methyl][3-(trimethoxysilyl)propyl]azanium (2-azaniumylethyl)[3-(trimethoxysilyl)propyl]amine 11-(4-ethenylphenyl)-10-[(4-ethenylphenyl)methyl]-3,3-dimethoxy-2-oxa-7,10-diaza-3-silaundecan-7-ium 11-(4-ethenylphenyl)-3,3-dimethoxy-2-oxa-7,10-diaza-3-silaundecan-7-ium 11-(4-ethenylphenyl)-7,10-bis[(4-ethenylphenyl)methyl]-3,3-dimethoxy-2-oxa-7,10-diaza-3-silaundecan-7-ium 11-(4-ethenylphenyl)-7-[(4-ethenylphenyl)methyl]-3,3-dimethoxy-2-oxa-7,10-diaza-3-silaundecan-7-ium hexachloride

Test material form:

liquid

Specific details on test material used for the study:

STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: stored in a closed container protected from heat, sparks and flame, protected from moisture or water, stored at room temperature
- Stability under test conditions: stable
- Solubility and stability of the test substance in the solvent/vehicle: The test material was soluble in the vehicle, N,N-Dimethylformamide (DMF).

In vivo test system

Test animals

Species:

mouse

Strain:

CBA:J

Sex:

female

Details on test animals and environmental conditions:

TEST ANIMALS
- Source: Harlan Sprague Dawley Inc., MD, USA
- Females nulliparous and non-pregnant: yes
- Age at study initiation: 10 weeks
- Weight at study initiation: 19.4 - 23.2 g
- Housing: animals were individually housed in suspended wire-mesh cages elevated over Bed-O´Cobs Combination bedding; animals were group housed for 5 h in a shoe-box tape cage (5 animals per cage) containing Bed-O´Cobs Combination bedding following tail vein injection of thymidine (3H-TdR); plastic tunnels were placed in each cage as an environmental enrichment device
- Diet: certified Rodent Diet #5002 (PMI International Inc.), ad libitum
- Water: municipal water, ad libitum
- Acclimation period: five days
- Indication of any skin lesions: baseline dermal score were recorded on study Day 1

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20.9 - 22.5
- Humidity (%): 52 - 58
- Air changes (per hr): 10 - 12
- Photoperiod (hrs dark / hrs light): 12/12

Study design: in vivo (LLNA)

Vehicle:

dimethylformamide

Concentration:

Range finding test:
- 10, 20, 40, 80 and 100% (v/v) in DMF
Main experiment:
- 20, 40 and 80% (v/v) in DMF

No. of animals per dose:

1 (range finding test)
5 (main test)

Details on study design:

PRE-SCREEN TESTS:
- Compound solubility: The test material was completely soluble in the vehicle (DMF). Test material concentrations of 10, 20, 40, 80 and 100% were used.
- Irritation: dermal scores were recorded on study Day 2 and 3.
- Ear thickness measurements: Ear thickness was measured on study Day 3.

MAIN STUDY
ANIMAL ASSIGNMENT AND TREATMENT
- Name of test method: [3H]-methyl thymidine (3H-TdR) incorporation
- Criteria used to consider a positive response: The test item will be regarded as a sensitiser if at least one concentration of the test item results in a threefold or greater increase in 3HTdR incorporation compared to control values. Any test item failing to produce a threefold or greater increase in 3H-TdR incorporation will be classified as a “non-sensitiser”.

TREATMENT PREPARATION AND ADMINISTRATION:
25 μl of the test item was applied to the dorsal surface of each ear of each mouse for three consecutive days; specifically, each day the dose was administered by applying a 12.5 µl aliquot to the left ear followed by an equal amount to the right ear. A further group of five mice received the vehicle or positive control alone in the same manner. Local irritation reactions were assessed. On day 6 an injection of 250 μl phosphate buffered saline (PBS) containing 20 μCi of [3H]-methyl
thymidine (3H-TdR) was made into the tail vein of each experimental mouse. Five hours later, the draining auricular lymph node of each ear was excised for each animal and pooled in a Stomacher sample bag containing 7 ml PBS. The lymph nodes were disaggregated by gentle mechanical disaggregation using a Stomacher 80 Lab System. The suspensions were centrifuged at 1000 rpm for 10 min at -4 °C. The pellets was re-suspended in 10 ml PBS and centrifuged again. Radioactive material was precipitated with 3 ml of 5% trichloroacetic acid at 4 °C for 18 hours. [3H]-TdR incorporation was measured by β-scintillation counting as disintegrations per minute (dpm).

Positive control substance(s):

hexyl cinnamic aldehyde (CAS No 101-86-0)

Statistics:

Data comparison was made using One Way Analysis of Variance (ANOVA) if the residues were normally distributed and the data had an equality of variance across the groups. Equality of variance was determined using Levene´s test. If the data did not satisfy the normality and equality of variance requirements, a Kruskal-Wallis test was performed. When an ANOVA or Kruskal-Wallis test was significant, pair-wise comparisons of the exposed groups or the positive control to the negative control were made using a Dunnett´s test or a Wilcoxon test, respectively. Using the disintegration per minute (dpm) data and the stimulation indexes, a quadratic regression on the dose levels was conducted using the data from the negative control and the 20, 40 or 80% test material groups. The resulting equation from the regression analysis for the stimulation index was used to determine the EC3 value.

Results and discussion

Positive control results:

A group of five animals was treated with 25 μl of the positive control substance alpha-hexylcinnamaldehyde (HCA) as a 25% solution in DMF. A further control group of five animals was treated with DMF alone. The stimulation index expressed as the mean radioactive incorporation for the treatment group divided by the mean radioactive incorporation of the vehicle control group is 11.6. Therefore, alpha-hexylcinnamaldehyde (HCA) was considered to be a sensitiser under the conditions of the test.

In vivo (LLNA)

Results

Results 1

Key result

Parameter:

SI

Value:

5.6

Test group / Remarks:

20% test material in DMF

Results 2

Key result

Parameter:

SI

Value:

10.9

Test group / Remarks:

40% test material in DMF

Results 3

Key result

Parameter:

SI

Value:

9.4

Test group / Remarks:

80% test material in DMF

Results 4

Key result

Parameter:

EC3

Value:

7

Test group / Remarks:

test material

Cellular proliferation data / Observations:

DETAILS ON STIMULATION INDEX CALCULATION
The stimulation index for each test group was calculated as followed: Stimulation index (SI) = mean dpm of test group / mean dpm of negative control group

CLINICAL OBSERVATIONS
Vehicle control animals as well as animals treated with 20 and 40% of the test material showed no notable observations. Animals treated with 80% test material showed no notable clinical observations on Day 1 and 2. Clinical observations were recorded on Days 3-6 and consisted of hair loss and flaking/scaling on the ears.
BODY WEIGHTS
The mean body weight for all groups indicated a mean body weight gain ranging from 1.62 to 4.83%.

DERMAL SCORE
Dermal scores on Day 6 were 0 for all groups except the group of mice treated with 80% test material where the dermal score was 2 (moderate irritation) for all animals in this group.

Any other information on results incl. tables

Table 1: Summary of LLNA result

Concentration (% in (v/v) DFM	mean dpm ± standard deviation	Stimulation index	Result
Vehicle	558.6 ± 308.7	1.0	Not applicable
20	3128.6 ± 2613.3	5.6	Positive
40	6086.8 ± 3463.8	10.9	Positive
80	5263.2 ± 1935.4	9.4	Positive
Positive control	6467.6 ± 2983.5	11.6	Positive

Applicant's summary and conclusion

Interpretation of results:

other: CLP/EU GHS criteria are met, Category 1B classification is required according to Regulations (EC) No 1272/2008.

Conclusions:

The stimulation indices (SI) obtained in the LLNA conducted with the test material at concentrations of 20, 40 and 80% in DMF (v/v) were greater than 3 in each case (5.6, 10.9 and 9.4%, respectively) with statistical evidence of a dose-response and, hence the test material is considered positive for contact sensitisation. The EC3 value was calculated as 7%.